ValiRx and Tangent Reprofiling joint venture (JV) ValiSeek has reported positive data from a Phase II clinical trial of VAL401 for the treatment of late-stage non-small cell lung cancer.

Evaluated by digital health company Ariana, the data demonstrated that VAL401 treatment has significantly improved patients’ quality of life and had a positive impact on the disease.

While analysing the study results, Ariana used its Knowledge Extraction and Management (KEM) advanced artificial intelligence technology to identify positive relations between response and pharmacokinetic parameters and between response and pre-treatment with particular chemotherapies.

This could lead to the potential for combining VAL401 with these particular chemotherapies.

“This data advocates the potential for VAL401 in treating very late-stage cancer patients in the palliative arena.”

The rate of progression-free survival (PFS), blood biochemistry, quality of life data obtained from the study were also assessed by Ariana.

ValiSeek CEO Dr Suzy Dilly said: “This data advocates the potential for VAL401 in treating very late-stage cancer patients in the palliative arena.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It also advocates the potential for VAL401, in the as yet untested combinations with, both traditional chemotherapies and immune-oncology treatments.

“Palliative stage patients could expect to see improvements in symptoms with the added benefit of improved survival prospects. This encouraging 60% overall response rate seen in this first all-comer trial provides a strong foundation for the next stage of clinical testing.”

According to Dilly, the measure of immune competency of the treated patients of the trial was also found to be highly effective.